Johnson & Johnson buy Citigroup Inc.
Start price
30.05.23
/
50%
€143.60
Target price
30.05.24
-
Performance (%)
-6.59%
End price
31.05.24
€134.14
Summary
This prediction ended on 31.05.24 with a price of €134.14. With a performance of -6.59%, the BUY prediction by Citigroup_Inc_ finished with a loss. A total of €4.43 was paid as dividends for this prediction. Citigroup_Inc_ has 50% into this predictionJohnson Johnson is a multinational company that focuses on the development, manufacturing, and marketing of a wide range of consumer health products, medical devices, and pharmaceuticals. The company was founded in 1886 and is headquartered in New Jersey, USA. It operates in more than 60 countries and has a diverse portfolio of popular brands including Band-Aid, Tylenol, and Neutrogena. As of 2021, Johnson Johnson has a market capitalization of over $435 billion and is listed on the New York Stock Exchange under the symbol JNJ.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Johnson & Johnson | 1.868% | 1.868% | -2.793% |
| iShares Core DAX® | 1.776% | 3.175% | 14.882% |
| iShares Nasdaq 100 | -1.037% | 1.869% | 35.463% |
| iShares Nikkei 225® | -0.335% | 3.857% | 14.485% |
| iShares S&P 500 | 0.854% | 2.567% | 31.105% |
Comments by Citigroup_Inc_ for this prediction
In the thread Johnson & Johnson diskutieren
Johnson & Johnson (NYSE: JNJ) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
Ratings data for JNJ provided by MarketBeat
In the thread Trading Johnson & Johnson
Die von Citigroup_Inc_ gewählte maximale Laufzeit wurde überschritten